Myriad Genetics Financials
Myriad Genetics (MYGN) reported $806.6M in revenue over the twelve months to Jun 30, 2026, down 3.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Myriad’s business still throws off high gross profit, but reported losses were dominated by balance-sheet resets rather than cash collapse.
Gross margin stability near70.0% and operating cash flow of$1.8M do not fit a business whose core economics suddenly deteriorated. Because goodwill fell by about$235M while reported losses widened sharply, the gap points to a large non-cash reset on the balance sheet rather than a matching collapse in day-to-day cash generation.
Gross margin held around
The balance sheet is being reconfigured: total assets dropped to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Myriad Genetics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Myriad Genetics has an operating margin of -47.0%, meaning the company loses $47 on every $100 of revenue. This results in a profitability score of 27/100. This is down from -14.7% the prior year.
Myriad Genetics's revenue declined 1.6% year-over-year, from $837.6M to $824.5M. This contraction results in a growth score of 49/100.
Myriad Genetics carries a low D/E ratio of 0.33, meaning only $0.33 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.49, Myriad Genetics holds $2.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.
Not available for Myriad Genetics, and counted as zero in the overall score.
Myriad Genetics posts a -99.5% return on equity (ROE), meaning it loses $99 for every $100 of shareholders' equity. This results in a returns score of 19/100. This is down from -18.1% the prior year.
Myriad Genetics scores -1.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($304.2M) relative to total liabilities ($338.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Myriad Genetics passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Myriad Genetics reported a net loss of $366.0M while generating $1.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Myriad Genetics reported an operating loss of $387.2M against $10.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Myriad Genetics generated $824.5M in revenue in fiscal year 2025. This represents a decrease of 1.6% from the prior year.
Myriad Genetics's EBITDA was -$333.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 435.3% from the prior year.
Myriad Genetics reported -$366.0M in net income in fiscal year 2025. This represents a decrease of 188.2% from the prior year.
Myriad Genetics earned -$3.95 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 180.1% from the prior year.
Cash & Balance Sheet
Myriad Genetics held $149.6M in cash against $119.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Myriad Genetics's gross margin was 69.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.
Myriad Genetics's operating margin was -47.0% in fiscal year 2025, reflecting core business profitability. This is down 32.2 percentage points from the prior year.
Myriad Genetics's net profit margin was -44.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 29.2 percentage points from the prior year.
Myriad Genetics's ROE was -99.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 81.3 percentage points from the prior year.
Capital Allocation
Myriad Genetics invested $106.8M in research and development in fiscal year 2025. This represents a decrease of 5.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
MYGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.7M-4.8% | $200.4M-4.5% | $209.8M+2.0% | $205.7M-3.5% | $213.1M+8.8% | $195.9M-7.0% | $210.6M-1.3% | $213.3M |
| Cost of Revenue | $63.7M+1.4% | $62.8M-0.3% | $63.0M+1.8% | $61.9M+1.0% | $61.3M-0.6% | $61.7M+3.4% | $59.7M-6.0% | $63.5M |
| Gross Profit | $127.0M-7.7% | $137.6M-6.3% | $146.8M+2.1% | $143.8M-5.3% | $151.8M+13.1% | $134.2M-11.1% | $150.9M+0.7% | $149.8M |
| R&D Expenses | $25.0M-7.7% | $27.1M+6.3% | $25.5M-9.6% | $28.2M+10.2% | $25.6M-6.9% | $27.5M-16.4% | $32.9M+15.4% | $28.5M |
| SG&A Expenses | $57.8M-7.1% | $62.2M+11.9% | $55.6M-18.1% | $67.9M+1.6% | $66.8M+0.5% | $66.5M+144.7% | -$148.7M-206.9% | $139.1M |
| Operating Income | -$38.9M-26.7% | -$30.7M-438.6% | -$5.7M+75.5% | -$23.3M+92.9% | -$329.2M-1035.2% | -$29.0M+25.8% | -$39.1M-95.5% | -$20.0M |
| Interest Expense | $4.1M0.0% | $4.1M-6.8% | $4.4M+15.8% | $3.8M+153.3% | $1.5M+87.5% | $800K+14.3% | $700K-12.5% | $800K |
| Income Tax | $600K | $0+100.0% | -$1.0M-183.3% | $1.2M+1300.0% | -$100K+99.7% | -$29.3M-987.9% | $3.3M+266.7% | $900K |
| Net Income | -$43.2M-26.7% | -$34.1M-326.3% | -$8.0M+70.8% | -$27.4M+91.7% | -$330.5M-330400.0% | -$100K+99.8% | -$42.2M-91.0% | -$22.1M |
| EPS (Diluted) | -$0.46-27.8% | -$0.36-414.3% | -$0.07+75.9% | -$0.29+91.9% | -$3.57 | $0.00+100.0% | -$0.47-95.8% | -$0.24 |
MYGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $638.9M-5.2% | $673.7M-4.7% | $706.6M-3.0% | $728.1M+7.5% | $677.3M-32.7% | $1.0B-2.1% | $1.0B-5.0% | $1.1B |
| Current Assets | $289.0M-7.6% | $312.8M-6.0% | $332.6M-3.5% | $344.8M+21.3% | $284.3M-1.0% | $287.2M-3.6% | $298.0M+1.6% | $293.2M |
| Cash & Equivalents | $115.2M-7.4% | $124.4M-16.8% | $149.6M+2.9% | $145.4M+95.4% | $74.4M-19.0% | $91.8M-10.4% | $102.4M+2.5% | $99.9M |
| Inventory | $30.6M+9.7% | $27.9M-8.8% | $30.6M-3.2% | $31.6M+10.1% | $28.7M+1.4% | $28.3M+2.9% | $27.5M+5.0% | $26.2M |
| Accounts Receivable | $109.5M-11.6% | $123.8M+7.4% | $115.3M-2.3% | $118.0M-13.9% | $137.0M+13.8% | $120.4M-0.7% | $121.2M-3.6% | $125.7M |
| Goodwill | $47.1M0.0% | $47.1M-8.7% | $51.6M0.0% | $51.6M0.0% | $51.6M-82.0% | $286.3M0.0% | $286.3M0.0% | $286.3M |
| Total Liabilities | $335.0M-0.4% | $336.3M-0.7% | $338.6M-4.7% | $355.3M+22.9% | $289.2M-4.0% | $301.2M-7.7% | $326.5M-6.6% | $349.6M |
| Current Liabilities | $130.7M+0.4% | $130.2M-2.7% | $133.8M-9.6% | $148.0M-26.0% | $199.9M+32.3% | $151.1M-7.9% | $164.1M+6.4% | $154.3M |
| Long-Term Debt | $120.7M+0.3% | $120.3M+0.3% | $119.9M+0.3% | $119.5M | N/A | $59.3M+49.7% | $39.6M+1.5% | $39.0M |
| Total Equity | $303.9M-9.9% | $337.4M-8.3% | $368.0M-1.3% | $372.8M-3.9% | $388.1M-44.9% | $704.9M+0.5% | $701.1M-4.2% | $731.7M |
| Retained Earnings | -$1.2B-3.7% | -$1.2B-3.0% | -$1.1B-0.7% | -$1.1B-2.5% | -$1.1B-43.7% | -$756.9M0.0% | -$756.8M-5.9% | -$714.3M |
MYGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.3M+47.1% | -$15.7M-248.1% | $10.6M-49.8% | $21.1M+255.1% | -$13.6M+16.6% | -$16.3M-347.0% | $6.6M+842.9% | $700K |
| Investing Cash Flow | -$3.2M+50.8% | -$6.5M-8.3% | -$6.0M+3.2% | -$6.2M+10.1% | -$6.9M+16.9% | -$8.3M-40.7% | -$5.9M-178.7% | $7.5M |
| Financing Cash Flow | $2.2M+173.3% | -$3.0M+63.4% | -$8.2M-114.6% | $56.2M+2061.5% | $2.6M-80.9% | $13.6M+547.6% | $2.1M+167.7% | -$3.1M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MYGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.6%-2.1pp | 68.7%-1.3pp | 70.0%+0.1pp | 69.9%-1.3pp | 71.2%+2.7pp | 68.5%-3.1pp | 71.7%+1.4pp | 70.2% |
| Operating Margin | -20.4%-5.1pp | -15.3%-12.6pp | -2.7%+8.6pp | -11.3% | -154.5% | -14.8%+3.8pp | -18.6%-9.2pp | -9.4% |
| Net Margin | -22.7%-5.6pp | -17.0%-13.2pp | -3.8%+9.5pp | -13.3% | -155.1% | -0.1%+20.0pp | -20.0%-9.7pp | -10.4% |
| Return on Equity | -14.2%-4.1pp | -10.1%-7.9pp | -2.2%+5.2pp | -7.3%+77.8pp | -85.2%-85.2pp | 0.0%+6.0pp | -6.0%-3.0pp | -3.0% |
| Return on Assets | -6.8%-1.7pp | -5.1%-3.9pp | -1.1%+2.6pp | -3.8%+45.0pp | -48.8%-48.8pp | 0.0%+4.1pp | -4.1%-2.1pp | -2.0% |
| Current Ratio | 2.21-0.2x | 2.40-0.1x | 2.49+0.2x | 2.33+0.9x | 1.42-0.5x | 1.90+0.1x | 1.82-0.1x | 1.90 |
| Debt-to-Equity | 0.400.0x | 0.360.0x | 0.330.0x | 0.32-0.4x | 0.75+0.7x | 0.080.0x | 0.060.0x | 0.05 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Myriad Genetics Ranks
Frequently Asked Questions
What is Myriad Genetics's annual revenue?
Myriad Genetics (MYGN) reported $824.5M in total revenue for fiscal year 2025. This represents a -1.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Myriad Genetics's revenue growing?
Myriad Genetics (MYGN) revenue declined by 1.6% year-over-year, from $837.6M to $824.5M in fiscal year 2025.
Is Myriad Genetics profitable?
No, Myriad Genetics (MYGN) reported a net income of -$366.0M in fiscal year 2025, with a net profit margin of -44.4%.
What is Myriad Genetics's EBITDA?
Myriad Genetics (MYGN) had EBITDA of -$333.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Myriad Genetics have?
As of fiscal year 2025, Myriad Genetics (MYGN) had $149.6M in cash and equivalents against $119.9M in long-term debt.
What is Myriad Genetics's gross margin?
Myriad Genetics (MYGN) had a gross margin of 69.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Myriad Genetics's operating margin?
Myriad Genetics (MYGN) had an operating margin of -47.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Myriad Genetics's net profit margin?
Myriad Genetics (MYGN) had a net profit margin of -44.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Myriad Genetics's return on equity (ROE)?
Myriad Genetics (MYGN) has a return on equity of -99.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Myriad Genetics's operating cash flow?
Myriad Genetics (MYGN) generated $1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Myriad Genetics's total assets?
Myriad Genetics (MYGN) had $706.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Myriad Genetics spend on research and development?
Myriad Genetics (MYGN) invested $106.8M in research and development during fiscal year 2025.
What is Myriad Genetics's current ratio?
Myriad Genetics (MYGN) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.
What is Myriad Genetics's debt-to-equity ratio?
Myriad Genetics (MYGN) had a debt-to-equity ratio of 0.33 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Myriad Genetics's return on assets (ROA)?
Myriad Genetics (MYGN) had a return on assets of -51.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Myriad Genetics's Altman Z-Score?
Myriad Genetics (MYGN) has an Altman Z-Score of -1.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Myriad Genetics's Piotroski F-Score?
Myriad Genetics (MYGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Myriad Genetics's earnings high quality?
Myriad Genetics (MYGN) reported a net loss of $366.0M while generating $1.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Myriad Genetics cover its interest payments?
Myriad Genetics (MYGN) reported an operating loss of $387.2M against $10.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Myriad Genetics?
Myriad Genetics (MYGN) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.